The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease

Abstract

INTRODUCTION: Antipsychotics have long been the mainstay of treatment for agitation and psychosis in Alzheimer's disease. Despite their current use successive studies have shown that they only confer a modest benefit which must be balanced against their well-established serious side effects (extrapyramidal symptoms, stroke, accelerated cognitive decline and mortality). Areas covered: This review outlines the current guidance on antipsychotic usage and the evidence of their continued usage against a backdrop of emerging pharmacological treatments and an increasing emphasis on the importance of non-pharmacological interventions. Expert Commentary: The current justification for antipsychotic us in the context the changing landscape of prescribing and provide a view on the most promising alternative candidates to this class of drug are appraised.